In response to the Ministry of Health's February 2012 issue of "Health Work Points" (hereinafter referred to as "Points"), Guotai Junan recently proposed in an interpretation report that the basic drug bidding system may shift.
The research report proposes that in 2012, the bidding policy for essential medicines system will shift from price-only to quality-first, which will be more conducive to the healthy and orderly development of the entire pharmaceutical industry, and trials will be carried out on the exclusive varieties, shortages, and suitable dosage forms for children in basic medicines. Pricing, fixed-point production, and basic drug policy environment are expected to become more benign.
Some industry researchers told the "Daily Economic News" reporter, "The basis for this shift may refer to the policies and announcements released in the future." The above report believes that the steady progress of the new rural cooperative medical insurance is expected to further expand the coverage of essential medicines, which is conducive to basic The drug system was further implemented in 2012.
The "Points" make it clear that the formulation of the National Essential Drug List (2012 edition), which is applicable to medical and health institutions at all levels, will be completed and the local regulations will be supplemented with non-catalogue drugs. At the same time, we must continue to standardize the procurement of essential drugs, adhere to bulk procurement, linking quantity and price, and recruiting and mining, and focus on basic drug distribution in rural and remote areas.
In response, the research report released by the first venture on the 7th also held that the implementation of unified national pricing for exclusive varieties of essential medicines will make the current essential medicines bid out of the cycle of winning bids for low prices, and will only be used in the bidding process. Service and quality do not attract prices. The above-mentioned industry researchers also stated that "the current system will indeed have the price first and ignore the quality."
According to Guo Fanli, a researcher in the pharmaceutical industry of China Investment Advisors, “In fact, due to the lack of compensation mechanisms, basic drugs have encountered many bottlenecks and are “crossing the river by feeling the stones.†As a whole, the appearance of the bizarre circles is mainly due to the Measured the price from the beginning."
According to the analysis of the first venture, the relevant species will skip the price bidding that is bothering for a long time. Directly targeting “quality and service†will help drug manufacturers reduce bidding costs; while increasing the winning rate of exclusive products, most companies are There is no problem on the service envelope. The “price†envelope is the key to the success or failure of tenders, and the implementation of uniform national pricing will greatly increase the success rate of winning the bid for the exclusive pharmaceutical manufacturer of essential drugs. Guojin Securities also believes that before the compensation mechanism of medical institutions can find a better solution, the reconstruction of the price system of medical insurance products in China will be a small probability event. Guo Fanli stated that "the effect of uniform pricing on exclusive products, etc. is limited, and there is still a difference from common products, and the solution to the compensation mechanism is fundamental." (Reporter Yang Hao)
The research report proposes that in 2012, the bidding policy for essential medicines system will shift from price-only to quality-first, which will be more conducive to the healthy and orderly development of the entire pharmaceutical industry, and trials will be carried out on the exclusive varieties, shortages, and suitable dosage forms for children in basic medicines. Pricing, fixed-point production, and basic drug policy environment are expected to become more benign.
Some industry researchers told the "Daily Economic News" reporter, "The basis for this shift may refer to the policies and announcements released in the future." The above report believes that the steady progress of the new rural cooperative medical insurance is expected to further expand the coverage of essential medicines, which is conducive to basic The drug system was further implemented in 2012.
The "Points" make it clear that the formulation of the National Essential Drug List (2012 edition), which is applicable to medical and health institutions at all levels, will be completed and the local regulations will be supplemented with non-catalogue drugs. At the same time, we must continue to standardize the procurement of essential drugs, adhere to bulk procurement, linking quantity and price, and recruiting and mining, and focus on basic drug distribution in rural and remote areas.
In response, the research report released by the first venture on the 7th also held that the implementation of unified national pricing for exclusive varieties of essential medicines will make the current essential medicines bid out of the cycle of winning bids for low prices, and will only be used in the bidding process. Service and quality do not attract prices. The above-mentioned industry researchers also stated that "the current system will indeed have the price first and ignore the quality."
According to Guo Fanli, a researcher in the pharmaceutical industry of China Investment Advisors, “In fact, due to the lack of compensation mechanisms, basic drugs have encountered many bottlenecks and are “crossing the river by feeling the stones.†As a whole, the appearance of the bizarre circles is mainly due to the Measured the price from the beginning."
According to the analysis of the first venture, the relevant species will skip the price bidding that is bothering for a long time. Directly targeting “quality and service†will help drug manufacturers reduce bidding costs; while increasing the winning rate of exclusive products, most companies are There is no problem on the service envelope. The “price†envelope is the key to the success or failure of tenders, and the implementation of uniform national pricing will greatly increase the success rate of winning the bid for the exclusive pharmaceutical manufacturer of essential drugs. Guojin Securities also believes that before the compensation mechanism of medical institutions can find a better solution, the reconstruction of the price system of medical insurance products in China will be a small probability event. Guo Fanli stated that "the effect of uniform pricing on exclusive products, etc. is limited, and there is still a difference from common products, and the solution to the compensation mechanism is fundamental." (Reporter Yang Hao)
With long range distance sensor with digital output, you can measure and monitor distances intergrated to your arduino, raspberry pi etc. The Laser Distance Sensor low cost is a competitive measure sensor, can measure from 3cm to 40m, 100m, max to 150m with +-1mm~+-3mm accuracy. Also, other requirements can be customized, like distance sensor analog output,long range ir sensor. We will give you full technical support when you testing our long distance sensor.
Long Range Distance Sensors,Long Range Sensor,Long Range Laser Sensor,Laser Ranging Sensor
Chengdu JRT Meter Technology Co., Ltd , https://www.cdlaserrangfinder.com